INTRODUCTION: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusions with other oncogenic drivers. MATERIALS AND METHODS: This retrospective study included patients enrolled in the Genomics England 100,000 Genomes Project who had linked clinical data from UK databases. Patients who had undergone tumor whole genome sequencing between March 2016 and July 2019 were included. Patients with and without NTRK fusions were matched. OS was analyzed along with oncogenic alterations in ALK, BRAF, EGFR, ERBB2, KRAS, and ROS1, and tumor mutation burden (TMB) and microsate...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
Gene fusions involving the neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3, are ...
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are emerging tissue-agnostic drug targe...
BackgroundNeurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various...
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tum...
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of ...
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to...
The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has ...
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with g...
Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular change...
International audienceThe advent of molecular biology resulted in the discovery of new oncogenes tha...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
Introduction: The neurotrophic tropomyosin-related kinase (NTRK) genes encode the tropomyosin recept...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
INTRODUCTION: The neurotrophic tropomyosin-related kinase (NTRK) genes encode the tropomyosin recept...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
Gene fusions involving the neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3, are ...
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are emerging tissue-agnostic drug targe...
BackgroundNeurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various...
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tum...
Purpose Neurotropic tropomyosin receptor kinase (NTRK) fusions have been identified in a variety of ...
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins referred to...
The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has ...
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with g...
Therapy with TRK inhibitors is a tumor-agnostic treatment directed against specific molecular change...
International audienceThe advent of molecular biology resulted in the discovery of new oncogenes tha...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
Introduction: The neurotrophic tropomyosin-related kinase (NTRK) genes encode the tropomyosin recept...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
INTRODUCTION: The neurotrophic tropomyosin-related kinase (NTRK) genes encode the tropomyosin recept...
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The dis...
Gene fusions involving the neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3, are ...
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are emerging tissue-agnostic drug targe...